Navigation Links
MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
Date:10/21/2013

of this single agent Phase I study are encouraging and further clinical development of ME-344 is warranted."

A copy of yesterday's poster presentation, entitled "ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study," is now available at www.meipharma.com.

ME-344 was generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Dose limiting toxicities were observed at both the 15 and 20 mg/kg dose levels, consisting primarily of Grade 3 peripheral neuropathy. Other medically significant adverse events observed in single patients included angina and QTc prolongation at the 10 mg/kg dose.

"We are encouraged by the results from this first-in-human study of ME-344," said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. "Not only did the trial show evidence of clinical activity, but the primary dose limiting toxicity was consistent with the proposed mechanism of action of ME-344, namely mitochondrial inhibition, suggesting on-target activity. Based on these findings, we are now actively preparing for a Phase Ib clinical trial of ME-344 in combination with Hycamtin® (topotecan) in small cell lung cancer and ovarian cancer, which we expect to initiate during the second quarter of 2014."

The Phase Ib trial will be designed to evaluate the safety and tolerability of ME-344 in combination with Hycamtin® in a total of 45 patients with either small cell lung cancer or ovarian cancer. Hycamtin® is a chemotherapy approved by the U.S. Food & Drug Administration for the treatment of small cell lung cancer and ovarian cancer, as well as cervical cancer.

About ME-344
ME-344 is MEI Pharma's isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause caspase-independent
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
2. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
3. ePharmaSolutions Wins Major Award for Life Sciences Industry Innovation
4. In Q1 Public Biopharmas Shift Fundraising into Overdrive
5. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
6. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
7. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
8. MEI Pharmas Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
11. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 RadiologyAuction will have their first auction ... product demonstrations at the end of the auction on ... Kodak and Fuji Cr,s, Agfa and Sony, printers and ... event. Various imaging equipment will be available at later ... After years of buying and selling imaging equipment, the ...
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... announces that a new market research report ... Byetta (Type 2 Diabetes) – Analysis ... http://www.reportlinker.com/p0657148/Byetta-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Byetta (Type ... 2020 Summary ...
... Reportlinker.com announces that a new market research ... Aesthetic Lasers and Energy Devices - ... http://www.reportlinker.com/p0575304/Aesthetic-Lasers-and-Energy-Devices---Global-Market-Briefing-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Beauty_Salon_and_Services Aesthetic Lasers ... 2017 Summary ...
Cached Medicine Technology:Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 5Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 2Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 3Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 4Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 5Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 7Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 8Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 9
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Jones Arena in Charlottesville, VA. McCartney is one ... music business and this beloved performer continues to roll along ... member of two legendary groups: Wings and The Beatles, has ... since 2013 on the “Out There” tour and has continually ...
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... Mother Hale Learning Center from Hale House. The Mother ... by offering high-quality, affordable Early Childhood Education. Sheltering Arms ... families will continue to be served by the center. ... serves 45 children ages six weeks to five years, ...
(Date:5/4/2015)... Rafael, CA (PRWEB) May 04, 2015 Unlike some ... foremost on imparting knowledge. The goal is to educate first ... the classroom. This ensures that the young runners are building ... careers. A few of the topics covered include Effort Based ... fast as I used to be? This is not a ...
(Date:5/4/2015)... In response to the proposed ... Force (USPSTF), Strategic Radiology® (SR®) fully aligns itself ... and Gynecologists (ACOG), the American College Of Surgeons, ... Society (ACS), American College of Radiology (ACR), and ... regular screening mammography for women beginning at age ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5
... to a recent Florida State University study, hospitals can ... IT// for all hospital operations. ,According to ... Manatee Memorial and Lakewood Ranch Medical Centre, have already ... few years. He said that, the hospitals are yet ...
... beyond the youth segments as far as their clientele is concerned. ... in Japan has taken to "Brain Train" concept like a duck ... million of its "Brain Training for Adults" game, which was released ... were not interested in video games ... But we did not ...
... are that is the medicine metformin is taken once daily ... ,In the words of co-author Dr. Bret Berner, "With ... 2000 mg a day. The new formulation, which goes by ... higher doses.” ,Dr. Bret Berner is chief scientific ...
... MIT scientists have developed a technology that uses the ... which function as in very thin lithium-ion batteries.// ... Yet-Ming Chiang have by simply manipulating a few genes ... the viruses grow and self-assemble into a functional electronic ...
... people who escaped from the horrifying attacks on the World ... depression, anxiety and other psychological problems even three years after ... Centers for Disease Control and Prevention said that the people ... breathing problems of a severe nature. "The trauma of being ...
... with the proposal of the Ministry of Health to hike ... ,"A committee has been set up to review fees ... private medical sector. This includes the licensing and renewal of ... of the medical or health establishments as well," said Dr ...
Cached Medicine News:Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
Plus cylinders only trial lens set....
Trial Lens Sets....
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Medicine Products: